ARMED WITH PROPEL

PROPEL®
MOMETASONE FUROATE SINUS IMPLANTS

PROPEL: PROVEN TECHNOLOGY, OUTCOMES YOU CAN TRUST

Six reasons to add PROPEL to your action plan



EXPLORE ALL 6 REASONS AT **PROPELOPENS.COM**

The PROPEL sinus implants are indicated to maintain patency and locally deliver steroid to the sinus mucosa in patients ≥18 years of age after sinus surgery: PROPEL for the ethmoid sinus, PROPEL Mini for the ethmoid sinus/frontal sinus opening, and PROPEL Contour for the frontal/maxillary sinus ostia. Contraindications include patients with intolerance to mometasone furoate (MF) or hypersensitivity to bioabsorbable polymers. Safety and effectiveness of the implant in pregnant or nursing females have not been studied. Risks may include, but are not limited to, pain/pressure, displacement of the implant, possible side effects of intranasal MF, sinusitis, epistaxis, and infection. For full prescribing information see IFU at www.IntersectENT.com/technologies/. Rx only.

intersect® ENT

PROPEL®
MOMETASONE FUROATE SINUS IMPLANTS

REASON 1
Individualized treatment options[1-3]

- **Family of 3 steroid-eluting implants** under one brand: PROPEL
- PROPEL promotes a tailored approach to postoperative care with **options** on implants':
  - indication
  - size
  - shape
  - delivery system
- The PROPEL implant provides localized delivery of mometasone furoate (MF), minimizing the reliance of patient compliance

REASON 2
Breakthrough technology[1-3]

- **2-in-1 mechanism:**
  - opens the sinuses
  - locally delivers MF, an advanced corticosteroid
- MF is:
  - **highly lipophilic**
  - **targeted and potent**
  - shown to have **low systemic bioavailability**
- PROPEL family of implants are bioabsorbable:
  - so implant **removal is not required**
- **Non-obstructive design** allows for:
  - mucociliary clearance
  - delivery of topical rinses

REASON 3
Robust, clinically proven benefits[1-3]

- Evaluated in >350 patients across **6 clinical studies**
- **Proven** in clinical trials to reduce:
  - **PROPEL:** the need for postoperative interventions, surgical interventions, and oral steroids, frank polyposis, significant adhesions, middle turbinate lateralization, patients' perceived burden of symptoms
  - **PROPEL Mini:** the need for postoperative interventions, surgical interventions, and oral steroids, occlusion/restenosis
  - **PROPEL Contour:** the need for postoperative interventions and surgical interventions, occlusion/restenosis, inflammation

REASON 4
Proven success in the real world[1-5]

- In **>300K patients since 2011** across all PROPEL family of implants
- PROPEL is supported by **Level 1-A evidence** to significantly improve outcomes of ethmoid sinus surgery
- **First and only** FDA-approved steroid-eluting sinus implants
- **PMA-approved**
- **15+** peer-reviewed publications

REASON 5
Efficacious across multiple patient types[4]

PROPEL demonstrated **efficacy across patient types:**

- With and without nasal polyps
- Undergoing primary or revision surgery
- Undergoing traditional or ballooning surgery

REASON 6
Intersect ENT partnership

- One of the only companies specifically **dedicated to innovation** in the field of otolaryngology
- Dedicated to improving the quality of life for patients with **ENT conditions** using robust clinical evidence
- Continued **collaboration** with physicians to innovate and transform CRS care

PROPEL implants are clinically proven to maintain patency and improve patient outcomes by targeting inflammation, the underlying cause of CRS.

CRS, chronic rhinosinusitis; MF, mometasone furoate.

References: 1. PROPEL [Instructions for Use]. Menlo Park, CA: Intersect ENT; 2013. **2.** PROPEL Mini [Instructions for Use]. Menlo Park, CA: Intersect ENT; 2016. **3.** PROPEL Contour [Instructions for Use]. Menlo Park, CA: Intersect ENT; 2016. **4.** Han JK, Marple BF, Smith TL, et al. Effect of steroid-releasing sinus implants on postoperative medical and surgical interventions: an efficacy meta-analysis. *Int Forum Allergy Rhinol*. 2012;2(4):271-279. **5.** Data on file, Intersect ENT, Inc. Calculated Patients-PROPEL Family. Q2 2019.

intersect® ENT